Illumina (ILMN) Expands TruSight Oncology Test With New KRAS CDx Collaborations

Illumina Inc. (NASDAQ:ILMN) ranks among the top NASDAQ stocks with low P/E ratios. On September 23, Illumina Inc. (NASDAQ:ILMN) announced that it would collaborate with several global pharmaceutical companies to create companion diagnostics (CDx) for KRAS biomarkers on its TruSight Oncology Comprehensive genomic profiling test.

The collaborations are intended to increase tumor-agnostic CDx claims for KRAS mutations, which are known to result in uncontrolled cell growth that can lead to cancer. By identifying genetic abnormalities that fuel the growth of cancer, the TruSight Oncology Comprehensive test creates molecular tumor profiles that assist physicians in matching patients with authorized targeted medicines or clinical trials.

Through pharmaceutical agreements, Illumina Inc. (NASDAQ:ILMN) stated it maintains an expanding pipeline of CDx claims in development to assist immunotherapies and targeted medicines.

Illumina Inc. (NASDAQ:ILMN) is a life sciences company that develops and produces tools and systems for genomic research. It provides a variety of tools and services, such as sequencing platforms and microarrays that allow clinicians to evaluate genetic data and make discoveries.

While we acknowledge the potential of ILMN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.